Q-omics provides the consensus-scored TCEAL6 profile across patient tissues and cancer cell-line models. TCEAL6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TCEAL6 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, TCEAL6 RNA expression shows 17,191 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRP, and GBM as cancer lineages where TCEAL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEAL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEAL6 survival associations across molecular data types. TCEAL6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEAL6 RNA expression–survival associations across cancer types. High TCEAL6 expression shows unfavorable associations in LIHC, COAD, DLBC and KIRP, but favorable associations in MESO and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TCEAL6 RNA expression.
This table summarizes TCEAL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TCEAL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEAL6 shows lower tumor expression in KIRP, KIRC, COAD, UCEC, THCA and HNSC. The KIRP box plot shows higher TCEAL6 RNA expression in normal versus tumor tissue (log2 FC = −0.612, t-test p < 0.001).
This table shows molecular features associated with TCEAL6 in patient tissues and cancer cell lines. In patient samples, TCEAL6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEAL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
